X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Prostate Cancer News

This page features general updates about prostate cancer, research and studies, hot topics, news articles and editorials. You also might be interested in ZERO’s Blog, which features inspiring stories, commentary, and insight into news and current events from contributors throughout the prostate cancer community.

Congressional Briefing Sheds Light on Latest USPSTF Prostate Cancer Scre...

Men's Health Network /
Advocacy Groups Declare "C" Recommendation for Men Aged 55-69 Can Save Lives. Read more ...

Results from Blue Earth Diagnostics’ LOCATE Trial Show 59% of Patients w...

Blue Earth Diagnostics, a molecular imaging diagnostics company, announced the topline results from an investigational clinical trial (“LOCATE”) evaluating the impact of 18F fluciclovine PET/CT imaging on patient management of biochemically recurrent prostate cancer after ...

A.I. to be Used as a ‘New Weapon’ in the UK’s Fight Ag...

Prime Minister Theresa May will lay out plans for the U.K. to use artificial intelligence (AI) and data in the diagnosis of chronic diseases. The plans will see roughly 22,000 fewer people dying from cancer ...

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prosta...

New findings support the safety of including selected men with Gleason 3+4 prostate cancer in active surveillance (AS) programs, Australian researchers reported at the American Urological Association 2018 annual meeting. Read more ...

Study Findings Complicate the Paradigm for Hormone-Sensitive Prostate Ca...

Clinical trial results that challenge the standard of care sometimes make it more difficult for physicians to decide how to treat their patients. Such is the case with the CHAARTED, LATITUDE, and STAMPEDE trials1-3, which ...

ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) P...

The Janssen Pharmaceutical Companies of Johnson & Johnson today presented a post-hoc analysis from the Phase 3 SPARTAN study that showed treatment with ERLEADA™ significantly reduced the risk of prostate specific antigen (PSA) progression in ...

New Data Reinforce Positive Impact of the Oncotype DX@ Genomic Prostate ...

Genomic Health, Inc. announced results from two new studies demonstrating the positive impact of the Oncotype DX@ Genomic Prostate ScoreT (GPST) test on risk assessment for better treatment decisions in clinically low-risk prostate cancer patients ...

Loading...

August 2016

July 2016

June 2016